Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 11Thoracic 3Breast 3Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Head & Neck 2Genitourinary 2Dermatologic 2Myeloid 1Gynecologic 1Classical hematology 1CNS 1

Conditions

Thyroid Neoplasms 13Thyroid Carcinoma, Anaplastic 9Colorectal Neoplasms 5Thyroid Cancer, Papillary 4Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Multiple Myeloma 3Melanoma 3Glioma 3Adenocarcinoma, Follicular 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Hematologic Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid cancer, follicular 1Thyroid cancer, Hurthle cell 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Refractory Differentiated Thyroid Gland Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Nonseminomatous germ cell tumor 1Neoplasms by Site 1Neoplasms by Histologic Type 1Mouth Neoplasms 1Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation 1Lymphoproliferative Disorders 1

Interventions

pembrolizumab 23Nivolumab 10Trastuzumab 7Gemcitabine 6Cisplatin 6Cetuximab 6Docetaxel 5spartalizumab 4atezolizumab 4Ipilimumab 4Drug Therapy 4Cyclophosphamide 4Carboplatin 4Capecitabine 4palbociclib 3fludarabine 3cemiplimab 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Erlotinib Hydrochloride 3Bortezomib 3ulixertinib 2trametinib 2sargramostim 2pertuzumab 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2aldesleukin 2Taxes 2TH 302 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × trametinib × Head & Neck × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT05907304 2026-02-27

SEACRAFT-1

Erasca, Inc.

Phase 1 Active not recruiting
86 enrolled
DermatologicGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡